Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Why we should have more collab...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Why we should have more collaboration on HTA in Europe: the example of sofosbuvir

Why we should have more collaboration on HTA in Europe: the example of sofosbuvir

Bibliographic Details
Main Authors: Hedi Schelleman, Rudy Dupree, Finn B Kristensen, Wim Goettsch
Format: Article
Language:English
Published: Taylor & Francis Group 2015-12-01
Series:Journal of Pharmaceutical Policy and Practice
Subjects:
Health Technology Assessment
Success Factor
Eastern European Country
Sofosbuvir
Promising Agent
Online Access:https://www.tandfonline.com/doi/10.1186/2052-3211-8-S1-O13
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://www.tandfonline.com/doi/10.1186/2052-3211-8-S1-O13

Similar Items

  • Combination of Sofosbuvir-Ledipasvir and Sofosbuvir- Daclatasvir for Treatment HCV Patients in Indonesia
    by: Andri Sanityoso Sulaiman, et al.
    Published: (2023-12-01)
  • Changes in tryptophan and phenylalanine in chronic HCV patients treated with direct acting antiviral (sofosbuvir)
    by: Eman G. Behiry, et al.
    Published: (2018-11-01)
  • Comparison of the Efficacy of Sofosbuvir and Kaletra on the Outcome of COVID-19. Is Sofosbuvir A Potential Treatment For COVID-19?
    by: Shahnaz Sali, et al.
    Published: (2020-12-01)
  • Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
    by: Andrew Hill, et al.
    Published: (2016-01-01)
  • Real-world effectiveness of sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir against genotype 3 hepatitis C virus infection: a systematic review and meta-analysis
    by: Liwei Zhuang, et al.
    Published: (2025-02-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs